Recent Trend of Generic Medicines Market In Japan

Size: px
Start display at page:

Download "Recent Trend of Generic Medicines Market In Japan"

Transcription

1 Recent Trend of Generic Medicines Market In Japan Joint 22 nd EGA and 19 th IGBA Annual Conference Dubrovnik, Croatia 9 June, 2016 Itsuro Yoshida President of Japan Generic Medicines Association Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 1 JGA : Japan Generic Medicines Association Founded: 1965 Members: 41 companies, 11 affiliate members (as of 2016/4) President: Itsuro Yoshida (since 2013) (President of Towa Pharmaceutical Co., Ltd.) JGA is the sole association in Japan which consists of Marketing Authorization Holders of generic medicines. JGA aims to contribute to the advancement of public health and welfare by supplying stably generic medicines with high quality and with reasonable price as well as to forwarding the common benefit of the members. JGA s English website Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 2 1

2 Transition of Population Population growth and forecast Total population: million million in 2010 Total population: million in years old and over: 34 million in years old and over: 39 million in years old and over Source) Population Statics 2015 by National Institute of Population and Social Security Research, Population Statics Data by Ministry of Internal Affairs and Communications Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 3 Future Population Structure in Japan Population Rate of 65 Years Old and Over 40% 35% 30% 29.1% 31.6% 30.3% 33.4% 38.8% 39.4%39.9% 37.7% 36.1% 25% 23.0% 26.8% Japan is now on the way to the full-fledged aging society. 20% 20.2% 15% 17.4% Source) National Institute of Population and Social Security Research Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 4 2

3 FY1991 FY1992 FY1993 FY1994 FY1995 FY1996 FY1997 FY1998 FY1999 FY2000 FY2001 FY2002 FY2003 FY2004 FY2005 FY2006 FY2007 FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2015 FY2025 Breakdown of National Medical Expenditure by Age Group (FY2013) The age group of 65 years old and over consumed 57.7% of total medical expenditure. Age group Expenditure (Trillion JPY) 0-14 years old years old years old years old and over % Total Source) The Ministry of Health, Labour and Welfare Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 5 Prediction of National Medical Expenditure The national medical expenditure is estimated to become about 61 trillion JPY in FY , , , , , , ,000 0 Medical Expenditure (trillion JPY) 45.7 Source) The Ministry of Health, Labour and Welfare Estimation ca years later estimation (in FY2025) ca.61trillion JPY = 550 billion USD = 470 billion EUR Current expenditure (in FY2015) 45.7 trillion JPY = 415 billion USD = 351 billion EUR Exchange Rate 1 USD = 110 JPY 1 EUR = 130 JPY Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 6 3

4 Development of National Policy for Promotion for Generic Medicine Use Action Program 2007 The MHLW issued Action program for Promotion of Generic Medicine Use in October Roadmap 2013 The MHLW issued Roadmap toward Further Promotion of Generic Medicine Use in April 2013, with new target aiming at share of 60% or above by the end of FY2017. Basic Policy on Economic and Fiscal Management and Reform 2015 Revision of Targeted Volume Share of Generics Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 7 Revision of Targeted Volume Share of Generics Basic Policy on Economic and Fiscal Management and Reform 2015 (30 th June 2015) The target volume share of generics has been revised from 60% or above by the end of FY2017 to 70% or above by mid-2017 as a step toward achieving 80% or above, and it is planned to attain the target goal of 80% or above at the earliest date possible between FY2018 and A detailed time-table for attaining 80% or above shall be finally set through evaluation of actual progress in volume share of generics by mid New Targeted Volume Share Step1 Step2 70% or above by mid % or above at the earliest date possible between FY2018 and Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 8 4

5 Schematic Figure of Targeted Volume Share of Generics 80.0% 70.0% Volume Share of Generics (%) 80% 70% Mid % 56.2% 60 % 50.0% 40.0% 30.0% 32.5% 34.9% 35.8% 39.9% 46.9% Former Target 60% or above by the end of FY % Source) The Ministry of Health, Labourand Welfare 1) Generic volume share from Sept.2005 to Sept.2015 are based on biennial drug price-volume market survey by the Government 2)The Ministry of Health, Labour and Welfare estimates that increasing the use of generics from nearly 47% volume share in FY2013 to 80% by FY2020 would save 1.3 trillion JPY. Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 9 Volume Share of Generics Comparing US and EU Countries Average Volume Share of Generics October September % 80% 8% 51% 17% 27% 43% 36% 35% 60% 40% 20% 92% 49% 83% 73% 57% 64% 65% Off-patent Originator Medicines Generics 0% Source) The Ministry of Health, Labour and Welfare on the basis of IMS,MIDAS, Market Segmentation, MAT Sept.2014 RX only Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 10 5

6 Overview of NHI-related Approaches for Promotion of Generic Use Fees Others Hospitals/Clinics Prescription Pharmacies Medical Fees Additional fee in Inpatients and Outpatients Services which use of generics over a certain ratio to pharmaceuticals replaceable by generics Additional fee for INN Prescribing Dispensing Fees Additional fee which dispense of generics over a certain ratio to pharmaceuticals replaceable by generics Fee for providing generic information to patients (Providing generic information has become one of the essential elements for obtaining a pharmacy care fee) Basic Rule for NHI Medical Services Prioritizing use of generics has been stipulated and guided. Change of Prescription Form Prescription form has been changed to facilitate substitution to generics. Substitution to Generics at Pharmacies Not only substitution of generics of the same strength and formulation as the reference innovator but also of different strengths and formulations (except for external drugs) is allowable. Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 11 Generic Penetration by Entry Year Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 12 6

7 FY1990 FY1992 FY1994 FY1996 FY1998 FY2000 FY2002 FY2004 FY2006 FY2008 FY2010 FY2012 FY2014 FY2016 Recent Trend of Volume Share of Generics 70% Volume Share of Generics (%) (Quarterly surveyed) 70% 60% 50% 40% 53.2% 49.8% 51.3% 49.5% 44.9% 43.1% 43.1% 54.4% 56.1% 54.2% 54.7% Source) JGA & IMS Japan Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 13 Pricing of Initial Entry Generics Initial generic prices fixed to the % of innovator medicine price In case of oral formulation 100% 80% 60% 40% 20% 0% Application Fiscal Year % of innovator medicine price - FY % FY % FY % FY % In case number of GE entry exceeds 10 FY % 60% FY % 50% FY % 40% Initial generics prices have been lowered. Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 14 7

8 Targeted Volume Share of Generic Medicines (by number of tablets) July March 2021 Sharp Increase of Target Volume Share FY (Targeted Share 80%) 100 billion Tablets Mid-2017(Targeted Share 70%) 84 billion Tablets Basic Policy on Economic and Fiscal Management and Reform 2015 (30 th June 2015) April March 2018 Roadmap Revision of Targeted Volume Share October 2007 March 2013 Action Program End of FY2017(Targeted Share 60%) 72 billion Tablets FY FY2012(Actual Share 40%) 43.5 billion Tablets Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 15 Status of Production Capacity and Capital Investment of Generic companies Billion Tablets Targeted volume by number of tablets 2012 (40%) 43.5 billion Tablets Mid-2017 (70%) 84 billion Tablets 2014 (52%) 56.5 billion Tablets (80%) 100 billion Tablets 20 0 Sum of production capacity of GE companies Actual (Oral formulations) Sum of production capacity of GE companies Forecast (Oral formulations) Capital Investment Amount : Total billion JPY Loans payable : Total billion JPY Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 16 8

9 Players in Japanese Generic Market Generic Companies Generic/Domestic Generic/Global Domestic Companies GE Market Growing Competition & Complexity Global Companies Innovator/Domestic Innovator/Global Innovator Companies Assuring stable supply is a key priority for all of players. Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 17 Summary 1. The expanding of generic medicine use is firmly positioned as a contribution tool to the sustainable national health insurance scheme for the coming aging society. 2. Generic companies are required to develop their production capacity and APIs procurement in response to sharp increase in demand of generics. The capital investment for increase of production capacity to meet 80% volume share has been in progress. 3. Sharply growing generic market carries with growing competition and downward pressure of prices. Efficient and tough shape of industrial structure will be requested not only for generic companies, but also for innovators in total. Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 18 9

10 Summary Further measures for promoting generic medicine may be limited by the era of 80% generic volume share. The demand to individual generic company in such era is to transform its company structure adapted to the environment of rapid growth based on the promotion of generic medicine use into that required for sustainable growth after rapid growth stage. Copyright 2016 Japan Generic Medicines Association All Rights Reserved. 19 Thank you very much for your kind attention Copyright 2016 Japan Generic Medicines Association All Rights Reserved

(Fig.) JPMA Industry Vision 2025

(Fig.) JPMA Industry Vision 2025 2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation

More information

Property right statement: Copyright of charts, tables and sentences in this report belongs to

Property right statement: Copyright of charts, tables and sentences in this report belongs to The Vertical Portal for China Business Intelligence. Semiconductor Equipment Industry Report, 2009 Nov/2009 Property right statement: Copyright of charts, tables and sentences in this report belongs to

More information

Opportunities and Challenges for Open Innovation

Opportunities and Challenges for Open Innovation WIPO REGIONAL SEMINAR ON TECHNOLOGY TRANSFER BY UNIVERSITY AND PUBLIC RESEARCH INSTITUTIONS THOROUGH THE STRATEGIC USE OF THE PATENT SYSTEM December 9-11, 29 Opportunities and Challenges for Open Innovation

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2017

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2017 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2017 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements

More information

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical

More information

FINLAND. The use of different types of policy instruments; and/or Attention or support given to particular S&T policy areas.

FINLAND. The use of different types of policy instruments; and/or Attention or support given to particular S&T policy areas. FINLAND 1. General policy framework Countries are requested to provide material that broadly describes policies related to science, technology and innovation. This includes key policy documents, such as

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2019

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2019 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Overview of Strategies and Plans Fiscal Year ending March 31, 2019 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements

More information

An Introduction to China s Science and Technology Policy

An Introduction to China s Science and Technology Policy An Introduction to China s Science and Technology Policy SHANG Yong, Ph.D. Vice Minister Ministry of Science and Technology, China and Senior Fellow Belfer Center for Science and International Affairs

More information

18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*)

18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*) 18 The Impact of Revisions of the Patent System on Innovation in the Pharmaceutical Industry (*) Research Fellow: Kenta Kosaka In the pharmaceutical industry, the development of new drugs not only requires

More information

EU S&T Tour Information Seminar HUNGARY. SZILÁGYI Balázs Consul General

EU S&T Tour Information Seminar HUNGARY. SZILÁGYI Balázs Consul General EU S&T Tour Information Seminar HUNGARY SZILÁGYI Balázs Consul General Hungary Population: 10 million Capital: 1,7 million EU member country: since 2004. Political system: parliamentary democracy Education

More information

China Ophthalmic Hospital Industry Report, May 2013

China Ophthalmic Hospital Industry Report, May 2013 China Ophthalmic Hospital Industry Report, 2012-2015 May 2013 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight

More information

THESIS PRESENTATION. Gabriele Goebel-Heise 5617A011-4

THESIS PRESENTATION. Gabriele Goebel-Heise 5617A011-4 THESIS PRESENTATION Gabriele Goebel-Heise 5617A011-4 RESEARCH FIELD Why knowledge transfer? Why collaborate? Why communicate difficult science & research topics? Why communicate and collaborate across

More information

Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd.

Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd. - Aiming to Create New Business Models and Expand Contribution to Patients - March 29, 2018

More information

Results in the JEREMIE implementation from a national development bank perspective

Results in the JEREMIE implementation from a national development bank perspective 3rd Annual JEREMIE & JESSICA Conference Warsaw, 28 October 2011 Results in the JEREMIE implementation from a national development bank perspective CSABA HARSÁNYI Brussels Representative Ministry for National

More information

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW Global Transcatheter Aortic Valve Replacement (TAVR) Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region, By Country: Opportunities and Forecast (2017-2022) By Type of Approach-

More information

2012 UN International Seminar for Global Agenda - The Population and Housing Census. Hyong-Joon Noh Statistics Korea

2012 UN International Seminar for Global Agenda - The Population and Housing Census. Hyong-Joon Noh Statistics Korea 2012 UN International Seminar for Global Agenda - The Population and Housing Census Hyong-Joon Noh Statistics Korea I II III IV V VI Concepts Background Action Plans Use of Administrative Data Future Plans

More information

The Science and Technology Basic Law (Unofficial Translation)

The Science and Technology Basic Law (Unofficial Translation) The Science and Technology Basic Law (Unofficial Translation) (Law No. 130 of 1995. Effective on November 15, 1995) Table of Contents Chapter 1 General Provisions (Articles 1-8) Chapter 2 Science and Technology

More information

Financial Results Briefing Session

Financial Results Briefing Session Financial Results Briefing Session Six-Month Period Ended September 30, 2017 November 8, 2017 SQUARE ENIX HOLDINGS CO., LTD. Statements made in this document with respect to SQUARE ENIX HOLDINGS CO., LTD.

More information

2.3 Trends Related to Research Performance

2.3 Trends Related to Research Performance 2.3 Trends Related to Research Performance The data on numbers of scientific papers, numbers of patents applied for and granted, technology trade balances, and high-tech product trade balances, which indicate

More information

The EU SME Policy in the Single Market Strategy

The EU SME Policy in the Single Market Strategy The EU SME Policy in the Single Market Strategy OBI - 29 February 2016 Dionysios TSAGKRIS dionysios.tsagkris@ec.europa.eu 15/03/2016 1 Single Market: facts and figures o Single Market: seeks to guarantee

More information

4. Vision 2: Providing innovative drugs to 8 billion people worldwide

4. Vision 2: Providing innovative drugs to 8 billion people worldwide 4. Vision 2: Providing innovative drugs to 8 billion people worldwide Strategic points for realizing the vision Responding to diverse needs and issues [Advanced countries] Promoting understanding of the

More information

Sony IR Day Game & Network Services Segment. November 25, Andrew House

Sony IR Day Game & Network Services Segment. November 25, Andrew House Sony IR Day 2014 November 25, 2014 Andrew House President and Group CEO Sony Computer Entertainment Inc. Group Executive in Charge of Network Entertainment Business Sony Corporation Agenda 1. Business

More information

Driving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China

Driving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China Driving profitable growth in Greater China Andy Ho Chief Market Leader Greater China Key takeaways China HealthTech market is the 2 nd largest globally and exhibits continued robust growth with significant

More information

New Industrial Structure Vision

New Industrial Structure Vision New Industrial Structure Vision About New Industrial Structure Vision The rapid pace of technological innovation is shaping the course of the future. This Fourth Industrial Revolution spurred by technologies

More information

Chapter No 6. Research Design and Methodology

Chapter No 6. Research Design and Methodology Chapter No 6 Research Design and Methodology 6.0 Introduction The chapter is included with the purpose of making clear the steps taken for the systematic completion of the research. The steps taken are

More information

HOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET:

HOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET: HOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET: T H E C A S E O F P H A R M A C E U T I C A L I N S U R A N C E I N C A N A D A, T H E U K A N D A U S T R A L I A CHEPA Seminar, April 2011 Katherine

More information

INDUSTRY OVERVIEW SOURCE OF INFORMATION

INDUSTRY OVERVIEW SOURCE OF INFORMATION This section contains information and statistics relating to the PRC economy and the industry in which we operate. We have derived such information and data partly from publicly available government and

More information

Technology and Industry Outlook Country Studies and Outlook Division (DSTI/CSO)

Technology and Industry Outlook Country Studies and Outlook Division (DSTI/CSO) OECD Science, Technology and Industry Outlook 2012 Directorate for Science Technology and Industry Directorate for Science, Technology and Industry Country Studies and Outlook Division (DSTI/CSO) What

More information

The Asia S&T Strategic Cooperation Promotion Program

The Asia S&T Strategic Cooperation Promotion Program Asia Disaster Reduction Science and Technology Forum The Asia S&T Strategic Cooperation Promotion Program Jakarta, December 4th, 2006 Akira YOSHIKAWA Deputy Director General Science & Technology Policy

More information

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective 1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation

More information

Capcom Co., Ltd. (Tokyo Exchanges, First Section, 9697) Results of Operations and Strategies First half of fiscal year ending March 31, 2014

Capcom Co., Ltd. (Tokyo Exchanges, First Section, 9697) Results of Operations and Strategies First half of fiscal year ending March 31, 2014 Capcom Co., Ltd. (Tokyo Exchanges, First Section, 9697) Results of Operations and Strategies First half of fiscal year ending March 31, 2014 0 Forward-looking Statements Strategies, plans, outlooks and

More information

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does

More information

Aqua Pharmaceuticals, LLC

Aqua Pharmaceuticals, LLC Aqua Pharmaceuticals, LLC Corporate Presentation June 2011 AQUA PHARMACEUTICALS, LLC 1 Company Overview Specialty dermatology pharmaceutical company currently focusing on acquiring, developing and marketing

More information

The relationship between a cost reduction in medical expenses and utilizing smart health services, and a driving factor in Japan

The relationship between a cost reduction in medical expenses and utilizing smart health services, and a driving factor in Japan The relationship between a cost reduction in medical expenses and utilizing smart health services, and a driving factor in Japan Yosuke NAKAJIMA*, Yutaka TAKAHASHI**, Naohiko KOHTAKE* *:Graduate School

More information

Summary of Operating Results for 2Q of the Fiscal Year Ending March 31, 2019

Summary of Operating Results for 2Q of the Fiscal Year Ending March 31, 2019 Summary of Operating Results for 2Q of the Fiscal Year Ending March 31, 2019 2Q of the fiscal year ending March 31, 2019 2Q of the fiscal year ended March 31, 2018 Fiscal year ended March 31, 2018 Net

More information

Research on Technological Innovation Capability Evaluation of Guangxi Pharmaceutical Industry

Research on Technological Innovation Capability Evaluation of Guangxi Pharmaceutical Industry Research on Technological Innovation Capability Evaluation of Guangxi Pharmaceutical Industry Xin Wang, Jun Hong & Peng Liu School of Electrical Engineering, Guangxi University 100 Da Xue Road, Nanning

More information

Recent Developments in Research and Innovation Policy in Japan

Recent Developments in Research and Innovation Policy in Japan Recent Developments in Research and Innovation Policy in Japan Kazuyuki Motohashi March 2003 WP#03-03 1 Recent Developments in Research and Innovation Policy in Japan March 31, 2003 Kazuyuki Motohashi

More information

Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, rd Quarter Report Fiscal year ending March 31, 2010

Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, rd Quarter Report Fiscal year ending March 31, 2010 Capcom Co., Ltd. Tokyo and Osaka Exchanges, First Section, 9697 3rd Quarter Report Fiscal year ending March 31, 2010 Precautions Concerning Forward-looking Statements Strategies, plans, outlooks and other

More information

China's Specialization in Innovative Manufacturing NAS Innovation Policy Forum May 23, 2017 Jonas Nahm, Johns Hopkins SAIS

China's Specialization in Innovative Manufacturing NAS Innovation Policy Forum May 23, 2017 Jonas Nahm, Johns Hopkins SAIS 1 China's Specialization in Innovative Manufacturing NAS Innovation Policy Forum May 23, 2017 Jonas Nahm, Johns Hopkins SAIS 1. Indigenous Innovation Policy (2006-2020) 2. Policy Implementation in Wind

More information

Where Do We Come From? What Are We? Where Are We Going?

Where Do We Come From? What Are We? Where Are We Going? Where Do We Come From? What Are We? Where Are We Going? - A Japanese Perspective on Japanese Science and Technology Policy (Where Do We Come From? What Are We? Where Are We Going?, Paul Gauguin, 1897)

More information

Potential effect on employment in developed and developing countries

Potential effect on employment in developed and developing countries Potential effect on employment in developed and developing countries By Dr. Edmundo Molina Expert Group Meeting on Exponential Technological Change, Automation and Their Policy Implications for Sustainable

More information

Results Briefing Session

Results Briefing Session Results Briefing Session The First-Half of the Fiscal Year Ending March 31, 2010 November 5, 2009 1 SQUARE ENIX HOLDINGS CO., LTD. Statements made in this document with respect to SQUARE ENIX HOLDINGS

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2018

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2018 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2018 0 Forward-looking Statements Strategies, plans, outlooks and other statements that are

More information

Message from the CEO. 4 OMRON Corporation

Message from the CEO. 4 OMRON Corporation Message from the CEO 4 OMRON Corporation Achieving growth through a stronger earnings structure. Solving social issues through new technologies and innovative concepts. Yoshihito Yamada President and CEO

More information

Achieved sales and profit growth with operating profit margin of 22%

Achieved sales and profit growth with operating profit margin of 22% Summary of Operating Results for 2Q of the Fiscal Year Ending March 31, 2018 Achieved sales and profit growth with operating profit margin of 22% (Million of yen) 2Q of the fiscal year ending March 31,

More information

Provided by. RESEARCH ON INTERNATIONAL MARKETS We deliver the facts you make the decisions

Provided by. RESEARCH ON INTERNATIONAL MARKETS We deliver the facts you make the decisions Provided by April 2015 PREFACE Market reports by ystats.com inform top managers about recent market trends and assist with strategic company decisions. A list of advantages ystats.com provides secondary

More information

[Overview of the Consolidated Financial Results]

[Overview of the Consolidated Financial Results] 0 1 [Overview of the Consolidated Financial Results] 1. Consolidated revenue totaled 5,108.3 billion yen, increased by 581.1 billion yen (+12.8%) from the previous year. 2. Consolidated operating profit

More information

Intellectual Property Strategic Program 2010

Intellectual Property Strategic Program 2010 Intellectual Property Strategic Program 2010 May 21, 2010 Intellectual Property Strategy Headquarters Intellectual Property Strategic Program 2010 Table of Contents I. Foreword... 1 II. Fundamental acknowledgment...

More information

FY2005 Results Briefing Session. May 24, 2006

FY2005 Results Briefing Session. May 24, 2006 FY2005 Results Briefing Session May 24, 2006 1 Statements made in this document with respect to SQUARE ENIX CO., LTD. and consolidated subsidiaries' (together, "SQUARE ENIX") plans, estimates, strategies

More information

Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO

Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking

More information

ASEAN Regulatory Harmonisation and Approval Process

ASEAN Regulatory Harmonisation and Approval Process ASEAN Regulatory Harmonisation and Approval Process Selvaraja Seerangam National Pharmaceutical Control Bureau Ministry of Health Malaysia Open Forum on Key Issues on TB Drug Development- 18-19 August

More information

Comprehensive Strategy on Science, Technology and Innovation 2014

Comprehensive Strategy on Science, Technology and Innovation 2014 June 24, 2014 Cabinet Decision Provisional Translation Comprehensive Strategy on Science, Technology and Innovation 2014 Bridge of Innovation toward Creating the Future Executive Summary Bureau of Science,

More information

Speaker/Panelist Profiles

Speaker/Panelist Profiles Speaker/Panelist Profiles Mr. Kenji Toda Chairperson, International Affairs Committee Japan Pharmaceutical manufacturers Association (JPMA) Senior Vice President, Government Relations

More information

Financing the Technology Innovation of SMEs in Korea. Hong Jae-Keun (Ph.D)

Financing the Technology Innovation of SMEs in Korea. Hong Jae-Keun (Ph.D) Financing the Technology Innovation of SMEs in Korea Hong Jae-Keun (Ph.D) CONTENTS Ⅰ. Why SME Technology Financing Matters? Ⅱ. How Korean SMEs Finance for R&D? Ⅲ. Sophisticated Technology Financing Infrastructure

More information

Commission on science and Technology for Development. Ninth Session Geneva, May2006

Commission on science and Technology for Development. Ninth Session Geneva, May2006 Commission on science and Technology for Development Ninth Session Geneva, 15-19 May2006 Policies and Strategies of the Slovak Republic in Science, Technology and Innovation by Mr. Stefan Moravek Head

More information

Ordinary and Extraordinary General Meeting. Brussels, May 24, 2012

Ordinary and Extraordinary General Meeting. Brussels, May 24, 2012 Ordinary and Extraordinary General Meeting Brussels, May 24, 2012 1 Results and accomplishments 2011 Count Georges Jacobs de Hagen Chairman of the Board of Directors of Delhaize Group 2 Tough economic

More information

2014 PRODUCTION FORECASTS FOR THE GLOBAL ELECTRONICS AND INFORMATION TECHNOLOGY INDUSTRIES

2014 PRODUCTION FORECASTS FOR THE GLOBAL ELECTRONICS AND INFORMATION TECHNOLOGY INDUSTRIES PRODUCTION FORECASTS FOR THE GLOBAL ELECTRONICS AND INFORMATION TECHNOLOGY INDUSTRIES December 24, JAPAN ELECTRONICS AND INFORMATION TECHNOLOGY INDUSTRIES ASSOCIATION FOREWORD For the Japanese economy,

More information

Promoting Foreign Direct Investment in The United States. Christopher Clement International Investment Specialist Invest in America

Promoting Foreign Direct Investment in The United States. Christopher Clement International Investment Specialist Invest in America Promoting Foreign Direct Investment in The United States Christopher Clement International Investment Specialist Invest in America FDI in the U.S. Economy 5.2 million $40 billion $55 billion $190 billion

More information

Digital Economy, Telecommunication and AI Network Policy in Japan

Digital Economy, Telecommunication and AI Network Policy in Japan Digital Economy, Telecommunication and AI Network Policy in Japan The 20th Annual Japan EU Conference 27 November 2017 Fondation Universitaire Mayu Terada, J.D.., LL.D. International Christian University

More information

Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background

Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background Local Production of Pharmaceuticals and Related Technology Transfer Dr. Padmashree Gehl Sampath Division for Technology and Logistics UNCTAD UNCTAD/CD-TFT 1 1 Background Case studies part of the EU funded

More information

The Role of Patients in Transitions of Care

The Role of Patients in Transitions of Care Play an Active Role It is crucial that you play an active role in your own healthcare. During treatment, you may see more than one provider. You also may visit more than one care setting. In each case,

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements

More information

Small Business, Entrepreneurship, and Economic Recovery

Small Business, Entrepreneurship, and Economic Recovery U.S. Department of Commerce Minority Business Development Agency Small Business, Entrepreneurship, and Economic Recovery Ivonne Cunarro Co- Hosted by the Kauffman Foundation, Federal Reserve Bank of Atlanta,

More information

LUPIN LIMITED Q3FY17 Investor Presentation February 09, 2017

LUPIN LIMITED Q3FY17 Investor Presentation February 09, 2017 LUPIN LIMITED Investor Presentation February 09, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based

More information

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade Medical Technology Association of NZ Proposed European Union/New Zealand Free Trade Agreement Submission to Ministry of Foreign Affairs & Trade February 2016 1 Introduction The Medical Technology Association

More information

Message from the CEO. Kazuhiro Tsuga. Representative Director President CEO. Panasonic Annual Report 2018

Message from the CEO. Kazuhiro Tsuga. Representative Director President CEO. Panasonic Annual Report 2018 Message from the CEO Kazuhiro Tsuga Representative Director President CEO 09 Panasonic Annual Report 2018 Growth Strategy Foundation for Growth Results for Fiscal Year Ended March 2018 Pushing Forward

More information

August 7, 2014 Heiwa Corporation

August 7, 2014 Heiwa Corporation August 7, 2014 Heiwa Corporation Contents Overview 3 1 st Quarter Results of FY Ending March 2015 4 Full-year Plan for FY2015 12 < Supplementary Information > Market Environment (Pachinko and Pachislot

More information

Briefing Session of Revisions to Consolidated Results Forecasts

Briefing Session of Revisions to Consolidated Results Forecasts Briefing Session of Revisions to Consolidated Results Forecasts Fiscal Year Ending March 31, 2013 March 26, 2013 1 SQUARE ENIX HOLDINGS CO., LTD. Statements made in this document with respect to SQUARE

More information

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in Feature Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia Based on our long-term strategic vision toward 2020, our goal is to become #1 in Asia in terms of our

More information

Recent Updates From CNIPA For Patent Application and examination

Recent Updates From CNIPA For Patent Application and examination Recent Updates From CNIPA For Patent Application and examination Sep 2018 CHEN PEI CONTENTS 01 02 Main Progress of CNIPA in 2017 Key Figures of CNIPA in 2017 03 Patent Application and Examination 2 CONTENTS

More information

EU S&T Tour Information Seminar HUNGARY. SZENTMÁRTONI Lívia Consul for Culture and Education

EU S&T Tour Information Seminar HUNGARY. SZENTMÁRTONI Lívia Consul for Culture and Education EU S&T Tour Information Seminar HUNGARY SZENTMÁRTONI Lívia Consul for Culture and Education Hungary Population: 10 million Capital: 1,7 million EU member country: since 2004. Political system: parliamentary

More information

FY2004 Results Briefing Session. May 24, 2005

FY2004 Results Briefing Session. May 24, 2005 FY2004 Results Briefing Session May 24, 2005 1 Statements made in this document with respect to SQUARE ENIX CO., LTD. and consolidated subsidiaries' (together, "SQUARE ENIX") plans, estimates, strategies

More information

Indicators, National Institute of Science and Technology Policy, MEXT

Indicators, National Institute of Science and Technology Policy, MEXT Research Material-274 Digest of Japanese Science and Technology Indicators 218 Oct. 218 Research Unit for Science and Technology Analysis and Indicators National Institute of Science and Technology Policy,

More information

Company Profile. Company Name. Shima Seiki Mfg., Ltd. (Stock code: 6222) President. Mitsuhiro Shima

Company Profile. Company Name. Shima Seiki Mfg., Ltd. (Stock code: 6222) President. Mitsuhiro Shima Company Profile Company Name President Main Business Established Capital Headquarters Shima Seiki Mfg., Ltd. (Stock code: 6222) Mitsuhiro Shima Manufacture and sale of computerized flat knitting machines,

More information

January 2018 Industrial Production

January 2018 Industrial Production Japan's Economy 28 February 2018 (No. of pages: 6) Japanese report: 28 Feb 2018 January 2018 Industrial Production Jan-Mar period expected to see lull in production growth trend Economic Research Dept.

More information

Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM. 15 th Annual Market Access Summit. Douglas Clark Executive Director PMPRB

Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM. 15 th Annual Market Access Summit. Douglas Clark Executive Director PMPRB Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM Douglas Clark Executive Director PMPRB 15 th Annual Market Access Summit Background Canada enacted a two-fold reform of its drug patent

More information

SEMICONDUCTOR INDUSTRY ASSOCIATION FACTBOOK

SEMICONDUCTOR INDUSTRY ASSOCIATION FACTBOOK Factbook 2014 SEMICONDUCTOR INDUSTRY ASSOCIATION FACTBOOK INTRODUCTION The data included in the 2014 SIA Factbook helps demonstrate the strength and promise of the U.S. semiconductor industry and why it

More information

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2016

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2016 Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2016 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements

More information

Mid/Long-Term Management Policy

Mid/Long-Term Management Policy Mid/Long-Term Management Policy Grand Design & Mid-Term Plan FY2018~FY2020 Yoshiaki Yoshida Representative Director & CEO Advantest Corporation April 26 th, 2018 Objectives of Grand Design and Mid-Term

More information

ble of Contents This is a licensed product of Ken Research and should not be copied

ble of Contents This is a licensed product of Ken Research and should not be copied ble of Contents 1 TABLE OF CONTENTS 1. India Paints Industry Introduction 1.1. Indian Paint Industry Value Chain 2. India Paints Industry Market Size, FY 2006-FY 2012 2.1. By Revenue, FY 2006-FY 2012 2.2.

More information

1Q04 Update: Silicon Demand Will Move to a Full Recovery

1Q04 Update: Silicon Demand Will Move to a Full Recovery Gartner Dataquest Alert 1Q04 Update: Silicon Demand Will Move to a Full Recovery Our latest silicon demand forecast indicates that wafer demand in 2003 will increase 9 percent over 2002. While the forecast

More information

The value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016

The value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016 The value of innovative pharmaceuticals and the potential for Vietnam Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016 PHARMA GROUP Our priority is to ensure that Vietnamese

More information

Health Care and Digital in Italy. Daniela Bianco, Partner e Responsabile Health Care Unit Alessandro Viviani, Principal Expert Digital Strategy

Health Care and Digital in Italy. Daniela Bianco, Partner e Responsabile Health Care Unit Alessandro Viviani, Principal Expert Digital Strategy Health Care and Digital in Italy Daniela Bianco, Partner e Responsabile Health Care Unit Alessandro Viviani, Principal Expert Digital Strategy Key drivers and Health Care evolution 1 2 ECONOMIC RESOURCES

More information

MARKET REPORT. Welcome to UAE The fastest growing healthcare Tourism destination in the world. Arab International Dental Conference & Exhibition

MARKET REPORT. Welcome to UAE The fastest growing healthcare Tourism destination in the world. Arab International Dental Conference & Exhibition MARKET REPORT Welcome to UAE The fastest growing healthcare Tourism destination in the world Middle East- the fastest growing Dental Markets in the world Abu Dhabi the Capital of UAE plays a pivotal role!

More information

Israel Venture Capital Investments Report Q3 2017

Israel Venture Capital Investments Report Q3 2017 Israel Venture Capital Investments Report Q3 2017 NOVEMBER 2017 Summary of Israeli Venture Capital Raising Q3/2017 +14% from Q2/2017 Israeli high-tech capital raising summed up to $1.44B @ ALL RIGHTS RESERVED.

More information

2010 HSC Economics Marking Guidelines

2010 HSC Economics Marking Guidelines 00 HSC Economics Marking Guidelines Section I Question Answer C D B 4 C 5 D 6 C 7 D 8 B 9 D 0 A D D C 4 B 5 A 6 A and D 7 C 8 B 9 A 0 B 00 HSC Economics Marking Guidelines Section II Question (a) Correctly

More information

The Evolution of Intellectual Property Products in the System of National Accounts: A Case Study of R&D Product Abstract Keywords: 1.

The Evolution of Intellectual Property Products in the System of National Accounts: A Case Study of R&D Product Abstract Keywords: 1. The Evolution of Intellectual Property Products in the System of National Accounts: A Case Study of R&D Product Lijia Tang Xiaoyan Song * Xiaobao Peng School of Public Affairs, University of Science and

More information

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS ORIGINAL: English DATE: November 1998 E TECHNOLOGY APPLICATION AND PROMOTION INSTITUTE WORLD INTELLECTUAL PROPERTY ORGANIZATION WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION

More information

CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.

CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment

More information

COUNTRY REPORT Intellectual Property Philippines

COUNTRY REPORT Intellectual Property Philippines COUNTRY REPORT Intellectual Property Philippines By Ms. Ronil Emmavi J. Remoquillo Intellectual Property Rights Specialist II The Philippines Capital: Manila Total Area 300,000 km 2 Population GDP Official

More information

2016 PHARMACEUTICAL PATENT OVERVIEW FOR VIETNAM

2016 PHARMACEUTICAL PATENT OVERVIEW FOR VIETNAM 216 PHARMACEUTICAL PATENT OVERVIEW FOR VIETNAM With a population approaching 1 million, a burgeoning health care industry, increasing consumer affluence, and relatively weak competition from local pharmaceutical

More information

Public Policies and Incentives for Smart Manufacturing in Turkey

Public Policies and Incentives for Smart Manufacturing in Turkey Public Policies and Incentives for Smart Manufacturing in Turkey Dr. Sinan Tandoğan Head of Entrepreneurship Support, TUBITAK sinan.tandogan@tubitak.gov.tr Industrial Technologies 2016, Amsterdam 22.06.16

More information

CHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come

CHINA MED DEVICE.   China Medtech Will Continue Its Double Digit Growth in Years to Come China Medtech Will Continue Its Double Digit Growth in Years to Come The high level characteristics of medtech in China is focused here. Each of the 6 specific sectors according to SWS recommendation will

More information

Regional Innovation Capability and Technology Transfer in Biotechnology Clusters (September 19 th 2013) : Yukiko NISHIMURA The University of Tokyo /

Regional Innovation Capability and Technology Transfer in Biotechnology Clusters (September 19 th 2013) : Yukiko NISHIMURA The University of Tokyo / Regional Innovation Capability and Technology Transfer in Biotechnology Clusters (September 19 th 2013) : Yukiko NISHIMURA The University of Tokyo / NPO PRIP Tokyo, Japan (Collaborator: Go Yoshizawa (Osaka

More information

Lupin Limited Annual Results FY12. Investor Presentation May being

Lupin Limited Annual Results FY12. Investor Presentation May being Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR

More information

Cross-Border R&D in China Understanding the Regulatory Challenges

Cross-Border R&D in China Understanding the Regulatory Challenges 1 2 Cross-Border R&D in China Understanding the Regulatory Challenges 1 Panelists Moderator: Paul A. Stewart, Silicon Valley Office Managing Partner, Foley & Lardner LLP Speakers: David Rosen, Partner,

More information

Fiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines

Fiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines Fifth Edition Fiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines April 2007 Ministry of the Environment, Japan First Edition: June 2003 Second Edition: May 2004 Third

More information

Chapter 5. Forms of Business Ownership and Organization

Chapter 5. Forms of Business Ownership and Organization Chapter 5 Forms of Business Ownership and Organization Learning Objectives 1 2 Discuss why most businesses are small businesses. Determine the contributions of small businesses to the economy. 7 Outline

More information

COM C. Rozwell

COM C. Rozwell C. Rozwell Research Note 6 October 2003 Commentary Technologies That Ease Pharmaceutical Industry Disruption Several disruptive forces are altering the life science business model. Enterprises must select

More information

Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan

Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan 2013/SOM1/LSIF/009 Agenda item: 17 Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan Purpose: Information Submitted by: United States Life Sciences and Innovative Forum Planning

More information